-
公开(公告)号：US20240150448A1
公开(公告)日：2024-05-09
申请号：US18545688
申请日：2023-12-19
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
CPC classification number: C07K16/18 , A61K38/2278 , A61P25/06 , C07K16/2869 , A61K2039/545 , C07K2317/34 , C07K2317/565 , C07K2317/92
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
公开(公告)号：US20240002545A1
公开(公告)日：2024-01-04
申请号：US18252442
申请日：2021-11-09
Applicant: AMGEN INC.
Inventor： Timothy RILEY , Fernando GARCES , Zhulun WANG , Bram Estes , Darren L. Bates
IPC: C07K16/46
CPC classification number: C07K16/468 , C07K2317/55 , C07K2317/64 , C07K2317/31
Abstract: The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic. Often, this implies extensive protein design with vary degrees of success. In the case of multispecific antibodies, the driving of the HC/LC pairing in the Fab region represents one of the most difficult challenges yet in the field of multispecific engineering. Described here is the discovery of a new single chain Fab module that utilizes a novel linker between VL-CL and VH-CH1 domains which will further enable the production of multispecifics.
-
公开(公告)号：US20220363770A1
公开(公告)日：2022-11-17
申请号：US17621189
申请日：2020-06-26
Applicant: AMGEN INC.
Inventor： Irwin CHEN , Su CHONG , Fernando GARCES , Mark Leo MICHAELS , Christopher MOHR , Kenneth William WALKER , Zhulun WANG , Neeraj Jagdish AGRAWAL , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Derek E. PIPER , Cen XU
Abstract: The present invention relates to antagonist antibodies of the human calcitonin gene-related peptide (CGRP) receptor as well as bispecific antigen binding proteins derived from the anti-CGRP antibodies that bind to and inhibit both the human CGRP receptor and another target, such as the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) receptor. Pharmaceutical compositions comprising the anti-CGRP receptor antibodies and bispecific antigen binding proteins as well as methods for producing them are also disclosed. Methods of using the anti-CGRP receptor antibodies and bispecific antigen binding proteins to ameliorate, treat, or prevent conditions associated with the CGRP and PAC1 receptors, such as chronic pain, migraine, and cluster headache, are also described.
-
公开(公告)号：US20220195022A1
公开(公告)日：2022-06-23
申请号：US17558032
申请日：2021-12-21
Applicant: AMGEN INC.
Inventor： Neeraj Jagdish AGRAWAL , Irwin CHEN , Su CHONG , Bryna FUCHSLOCHER , Kevin GRAHAM , Agnes Eva HAMBURGER , Mark Leo MICHAELS , Christopher MOHR , Derek E. PIPER , Kenneth William WALKER , Zhulun WANG , Cen XU
Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
公开(公告)号：US20240368292A1
公开(公告)日：2024-11-07
申请号：US18611364
申请日：2024-03-20
Applicant: Amgen Inc.
Inventor： Dirk E. SMITH , Ian FOLTZ , Chadwick T. KING , Ai Ching LIM , Rutilio CLARK , Michael R. COMEAU , Randal R. KETCHEM , Donghui SHI , Xiaoshan MIN , Zhulun WANG
Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
-
Patent Agency Ranking
公开(公告)号：US20230322867A1
公开(公告)日：2023-10-12
申请号：US18006689
申请日：2021-07-22
Applicant: AMGEN INC.
Inventor： Fernando GARCES , Zhulun WANG , Timothy RILEY
IPC: C07K14/165 , C12N15/85 , C07K16/10
CPC classification number: C07K14/165 , C07K16/10 , C12N15/85 , A61K2039/505
Abstract: The present invention relates to severe acute respiratory syndrome coronavirus 2 (“SARS-CoV2”) immunogens useful for the generation of therapeutic antibodies and vaccine development. Such therapeutic antibodies include human antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein, and that function to neutralize SARS-CoV2. The present invention also relates to methods of generating antibodies and antigen-binding portions thereof that specifically bind to human SARS-CoV2 S protein.
-
公开(公告)号：US20220119537A1
公开(公告)日：2022-04-21
申请号：US17339301
申请日：2021-06-04
Applicant: Amgen Inc.
Inventor： Dirk E. SMITH , Ian FOLTZ , Chadwick T. KING , Ai Ching LIM , Rutilio CLARK , Michael R. COMEAU , Randal R. KETCHEM , Donghui SHI , Xiaoshan MIN , Zhulun WANG
Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
-
公开(公告)号：US20210079051A1
公开(公告)日：2021-03-18
申请号：US17094968
申请日：2020-11-11
Applicant: AMGEN INC.
Inventor： Yumei XIONG , Yi ZHANG , Jackie Z. ZHENG , Agnes Eva HAMBURGER , Murielle M. VENIANT-ELLISON , Grant SHIMAMOTO , Xiaoshan MIN , Zhulun WANG , Jie TANG , Gunasekaran KANNAN , Marissa MOCK , Kenneth William WALKER
IPC: C07K14/475
Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
公开(公告)号：US20220402985A1
公开(公告)日：2022-12-22
申请号：US17836425
申请日：2022-06-09
Applicant: Amgen Inc.
Inventor： Darren L. BATES , Zhi LIU , TaeWeon LEE , Mark L. MICHAELS , Zhulun WANG
IPC: C07K14/485 , A61P9/10
Abstract: The present invention relates to engineered neuregulin-1 variants that selectively activate ErbB4 receptors but do not activate ErbB3 receptors. The invention also provides methods for using such variants to treat heart failure.
-
公开(公告)号：US20210087286A1
公开(公告)日：2021-03-25
申请号：US16623750
申请日：2018-06-20
Applicant: AMGEN INC.
Inventor： Darren L. BATES , Donghui SHI , David J. LLOYD , Pavel BONDARENKO , Mark L. MICHAELS , Todd HAGER , Xiaoshan MIN , Aiko UMEDA , Irwin CHEN , Zhulun WANG
Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
-
-
-
-
-
-
-
-
-
Search Results
31
records
(took 0.016 seconds)
